Biodexa Pharmaceuticals Plc (BDRX)

Biodexa Pharmaceuticals Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.38	0.7	0.58	0.34
Revenue Growth (YoY)	-	-45.49%	20.93%	68.51%	-49.11%
Cost of Revenue	5.44	4.07	5.11	4.65	6.07
Gross Profit	-5.44	-3.69	-4.41	-4.08	-5.73
Selling, General & Admin	3.79	3.03	4.54	2.95	4.96
Other Operating Expenses	-0.03	-0.01	-0.02	-0.02	-0.01
Operating Expenses	3.76	3.02	4.52	2.92	4.95
Operating Income	-9.2	-6.7	-8.93	-7	-10.67
Interest Expense	-0.17	-0.04	-0.05	-0.04	-0.03
Interest & Investment Income	0.17	0.08	0.03	-	0
Other Non Operating Income (Expenses)	3.22	0.49	0.47	0.94	-0.4
EBT Excluding Unusual Items	-5.98	-6.18	-8.49	-6.11	-11.1
Impairment of Goodwill	-	-	-	-	-2.29
Asset Writedown	-	-	-	-	-10.08
Other Unusual Items	-	-1.31	-	-	-
Pretax Income	-5.98	-7.49	-8.49	-6.11	-23.47
Income Tax Expense	-0.25	-0.41	-0.83	-0.65	-1.28
Earnings From Continuing Operations	-5.73	-7.08	-7.66	-5.46	-22.19
Net Income	-5.73	-7.08	-7.66	-5.46	-22.19
Net Income to Common	-5.73	-7.08	-7.66	-5.46	-22.19
Shares Outstanding (Basic)	0	0	-	-	-
Shares Outstanding (Diluted)	0	0	-	-	-
Shares Change (YoY)	1468.08%	-	-	-	-
EPS (Basic)	-11.57	-224.13	-	-	-
EPS (Diluted)	-11.57	-224.13	-	-	-
Free Cash Flow	-12.27	-6.85	-7.11	-6.33	-9.51
Free Cash Flow Per Share	-24.77	-216.94	-	-	-
Operating Margin	-	-1759.58%	-1277.83%	-1210.73%	-3111.08%
Profit Margin	-	-1858.01%	-1095.28%	-944.64%	-6469.10%
Free Cash Flow Margin	-	-1798.42%	-1017.17%	-1094.81%	-2772.60%
EBITDA	-9.08	-6.56	-8.76	-6.79	-9.57
D&A For EBITDA	0.12	0.14	0.17	0.21	1.1
EBIT	-9.2	-6.7	-8.93	-7	-10.67
Revenue as Reported	-	-	-	-	0.34

Updated Sep 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q